Poland’s Health Ministry is simplifying drug advertising regulations for healthcare professionals, shifting from extensive paper materials to digital formats starting April 15th.
Revolution in Drug Advertising
The Ministry of Health is streamlining regulations for drug advertising aimed at professionals, prioritizing digitization over bulky paper brochures. The new rules respond to deregulation demands intended to generate savings and modernize medical information flow.
Outdated Regulations
Current regulations regarding drug advertising to prescribers and pharmacists are widely considered outdated. Companies are currently obligated to physically deliver comprehensive product data, consistent with the Summary of Product Characteristics (SmPC). This requirement has become anachronistic and generates unnecessary costs and resource waste in the digital age.
New Regulation and Deregulation
The change comes with a new regulation from the Minister of Health on April 15th, amending the regulation on drug advertising, implementing deregulation postulate no. MZ-39-458. The Government Deregulation Team determined the existing model is ineffective and requires urgent adaptation to modern technological standards.
Hybrid Information Model
The key innovation is the diversification of information delivery. The Ministry of Health has decided to divide data into “key” and “supplementary” categories.
Key Information Remains Physical
Information of the highest importance will continue to be delivered in traditional paper form. This includes the product name (including the commonly used name), qualitative and quantitative composition of active and key excipients, pharmaceutical form, details of the responsible party, and availability category.
Digitization of Supplementary Data
The remaining data, considered less critical for initial advertising contact, can be provided electronically, such as through digital platforms or websites maintained by the responsible parties.
Data to be Digitized
Data to be digitized includes therapeutic indications, detailed dosage, contraindications, special warnings, descriptions of adverse reactions, and the marketing authorization number. Information about the availability category remains in traditional form, despite being covered by Article 54 of the Pharmaceutical Law.
Impact on Market Participants
The amendment will affect three main groups: responsible parties (approximately 350 companies), healthcare professionals (approximately 600,000 people), and the Chief Pharmaceutical Inspector (GIF). Manufacturers and distributors will see cost optimization, while doctors and pharmacists will gain easier digital access to detailed data.
GIF’s Role and Economic Justification
The GIF will need to adapt its control mechanisms to the new model. While the project doesn’t specify amounts, the emphasis on “economics of advertising processes” suggests a financial basis for the change, minimizing costs and promoting a more ecological and modern approach to pharmaceutical marketing.
